Mostrar el registro sencillo del ítem

Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience

dc.rights.licenseopenen_US
dc.contributor.authorSELLAMI, L.
dc.contributor.authorRUCHETON, B.
dc.contributor.authorBEN YOUNES, I.
dc.contributor.authorCAMUZAT, A.
dc.contributor.authorSARACINO, D.
dc.contributor.authorRINALDI, D.
dc.contributor.authorEPELBAUM, S.
dc.contributor.authorAZUAR, C.
dc.contributor.authorLEVY, R.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorAURIACOMBE, Sophie
dc.contributor.authorHANNEQUIN, D.
dc.contributor.authorPARIENTE, J.
dc.contributor.authorBARBIER, M.
dc.contributor.authorBOUTOLEAU-BRETONNIÈRE, C.
dc.contributor.authorCOURATIER, P.
dc.contributor.authorPASQUIER, F.
dc.contributor.authorDERAMECOURT, V.
dc.contributor.authorSAUVÉE, M.
dc.contributor.authorSARAZIN, M.
dc.contributor.authorLAGARDE, J.
dc.contributor.authorROUÉ-JAGOT, C.
dc.contributor.authorFORLANI, S.
dc.contributor.authorJORNEA, L.
dc.contributor.authorDAVID, I.
dc.contributor.authorLEGUERN, E.
dc.contributor.authorDUBOIS, B.
dc.contributor.authorBRICE, A.
dc.contributor.authorCLOT, F.
dc.contributor.authorLAMARI, F.
dc.contributor.authorLE BER, I.
dc.date.accessioned2021-02-26T10:55:32Z
dc.date.available2021-02-26T10:55:32Z
dc.date.issued2020
dc.identifier.issn0197-4580en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26362
dc.description.abstractEnGRN mutations are frequent causes of familial frontotemporal degeneration. Although there is no clear consensual threshold, plasma progranulin levels represent an efficient biomarker for predicting GRN mutations when decreased. We evaluated plasma levels to determine whether it could also predict age at onset, clinical phenotype, or disease progression in 160 GRN carriers. Importantly, progranulin levels were influenced by gender, with lower levels in male than in female patients in our study. Although we found no correlation with age at onset or with clinical phenotype, we confirmed that decreased level predicts GRN mutations, even in presymptomatic carriers more than four decades before disease onset. We also provided first evidence for the stability of levels throughout longitudinal trajectory in carriers, over a 4-year time span. Finally, we confirmed that progranulin levels constitute a reliable, cost-effective marker, suitable as a screening tool in patients with familial frontotemporal degeneration, and more broadly in patients without family history or with atypical presentations who are less likely to be referred for molecular diagnosis.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectSEPIA
dc.title.enPlasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience
dc.title.alternativeNeurobiol Agingen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.neurobiolaging.2020.02.014en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.journalNeurobiology of Agingen_US
bordeaux.page167.e1-167.e9en_US
bordeaux.volume91en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamSEPIAen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurobiology%20of%20Aging&rft.date=2020&rft.volume=91&rft.spage=167.e1-167.e9&rft.epage=167.e1-167.e9&rft.eissn=0197-4580&rft.issn=0197-4580&rft.au=SELLAMI,%20L.&RUCHETON,%20B.&BEN%20YOUNES,%20I.&CAMUZAT,%20A.&SARACINO,%20D.&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_NA_2020_Sellami.pdf
Tamaño:
722.2Kb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
811bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem